[go: up one dir, main page]

US3636219A - Anticholinergic compositions containing certain thiazolines or imidazolines - Google Patents

Anticholinergic compositions containing certain thiazolines or imidazolines Download PDF

Info

Publication number
US3636219A
US3636219A US348884A US3636219DA US3636219A US 3636219 A US3636219 A US 3636219A US 348884 A US348884 A US 348884A US 3636219D A US3636219D A US 3636219DA US 3636219 A US3636219 A US 3636219A
Authority
US
United States
Prior art keywords
carbons
group
weight
alkyl
thiazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US348884A
Inventor
Rudolf Culik
Jurg A Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Application granted granted Critical
Publication of US3636219A publication Critical patent/US3636219A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms

Definitions

  • This invention relates to pharmaceutical compositions useful for both human and veterinary applications. More particularly, this invention relates to synergistic utilization of one or more centrally acting anticholinergic substances and one or more of a class of central nervous sys tern depressants.
  • centrally acting anticholinergics are a well-recognized class of pharmacologically active substances. As is well known and understood by pharmacologists, these anticholinergics can be naturally occurring or synthetic and are those substances which act to inhibit and have a highly selective blocking action on effector organs innervated by postganglionic cholinergic nerves. As is known to persons skilled in this art, anticholinergic agents containing a quaternary nitrogen moiety are of course not centrally actmg.
  • Adephenine also identified as Trasentine (registered trademark) and Z-diethylaminoethyl diphenylacetate ice benactyzine, also identified as beta-diethylaminoethyl benzilate benztropine, also identified as 3-diphenyhnethoxytropane caramiphen, also identified as 1-phenylcyclopentanecarboxylic acid, diethylaminoethyl ester cyclopentolate, also identified as l-hydroxy-alphaphenylcyclopentaneacetic acid, Z-dimethylaminoethyl ester cycrimine, also identified as alpha-cyclopentylalpha-phen yl-l-piperidinepropanol ditran, also identified as N-ethyl-3-piperidyl phenyl cyclopentyl glycolate ethopropazine, also identified as IO-(Z-diethylaminopropyl) phen
  • centrally acting anticholinergics will most often be used in the form of an acid addition salt with an acid having a pharmaceutically aceptable anion.
  • pharmaceutically acceptable anion has a definite meaning to one skilled in the art,
  • Atropine is preferably used as the hydrobromide, hydrochloride, methylbrornide, methylnitrate, salicylate, sulfate, atropinesulfuric acid, valerate, aurichloride, platinichloride, oxalate or picrate; scopolamine as the hydrobromide, hydrochloride, aurichloride, auribromide, picrate, methylbromide, methylnitrate or aminoxide; Adephenine (registered trademark) as the hydrochloride; 'benactyzine as the hydrochloride; benztropine as the methanesulfonate; caramiphen as the hydrochloride or ethanedisulfonate; cycrimine as the hydrochloride; oxyphencyclimine as the hydrochloride; systral as the hydrochloride; and trihexyphenidyl
  • the second essential ingredient of the synergistic compositions of the present invention is a 2-arylamino-2- thiazoline or a 2-arylamino-2-imidazoline having central nervous system depressant activity.
  • Suitable Z-arylaminothiazolines or 2-arylamino-2-imidazolines include those of the following formulas:
  • R xix-n X-(L-R)-(L-R In each of the above formulas, X is S or N; R, R R and R are the same or different and can each be hydrogen or an alkyl group of 1 through 4 carbons with the total number of carbons in these 4 substituents being a maximum of 8.
  • the hydrogen atoms in the naphthyl, the partially reduced naphthyl or the indanyl groups may be replaced with substituents such as halogen, e.g., chlorine, bromine, fluorine and iodine, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy. Up through three such substituents can be present.
  • substituents such as halogen, e.g., chlorine, bromine, fluorine and iodine, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy. Up through three such substituents can be present.
  • A can be hydrogen, alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons, and preferably 1 or 2 carbons, or halogen including chlorine, bromine and fluorine;
  • B can be alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons and preferably 1 or 2 carbons, or halogen including chlorine, bromine and fluorine;
  • C can be hydrogen, alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons and preferably 1 or 2 carbons, halogen including chlorine, bromine and fluorine, alkylthio of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxyalkyl wherein the alkoxy portion has 1 or 2 carbons and the alkyl portion has 1 or 2 4 carbons, alkylamino of 1 or 2 carbons, dialkylamino where the alkyl group can be the same or dilferent and
  • the thiazoline compounds used in this invention are made in the manner described for the thiazoline compounds of U5. Pat. 2,027,030. Appropriate substitution of starting materials such as naphthyl-isothio-cyanates and indanyl-isothio-cyanates for the phenyl-isothiocyanates will produce the desired compounds.
  • the imidazoline compounds used in this invention are made in the manner described for the imidazolines of US. Pat. 2,899,426. Appropriate substitution of starting materials as will be known to an expert in the art produces the desired compounds.
  • the compounds used in this invention are crystalline solids. They can be readily prepared by reaction of the appropriately selected arylamine and an appropriate alkyl thiocyanate to form the corresponding N-aryl-N'-(beta-substituted ethyl)thiourea, followed by heating in a suitable solvent to close the thioazoline ring.
  • the thiourea can be prepared by reaction between an appropriate aryl thiocyanate and an appropriate alkylamine followed by the ring closure.
  • the reaction between the amine and thiocyanate can conveniently be carried out in a suitable inert organic solvent including both aromatic and aliphatic hydrocarbon solvents.
  • Halogenated, oxygenated or nitrated hydrocarbon solvents are useful.
  • Representative solvents are benzene, chloroform, carbon tetrachloride, ethylene dichloride, chlorobenzene, toluene, xylene, nitrobenzene, and nitrotoluene.
  • Temperatures in the range from 0 to C. are suitable.
  • the thiazolines, and the irnidazolines produced will be hydrobromides, hydrochlorides, hydriodides, methanesulfonic acids or p-toluenesulfonic acids. These acids can be converted to other pharmaceutically acceptable acids by procedures well known to those skilled in the art.
  • One highly useful method comprises contacting the acid addition salt with a basic anion exchange resin, for example, a highly basic compound such as the one available from Rohm & Haas Company under the name Amberlite IRA-400.
  • This resin is a polyquaternary ammonium compound which is prepared by chloromethylatiug a highly cross-linked copolymer of styrene and divinylbenzene followed by treatment of the chloromethylated material with a tertiary amine such as trimethylamine.
  • an acid addition salt of this invention for example, the citrate, the resin is first contacted with an aqueous solution of citric acid whereupon an anion exchange takes place converting the quaternary halide to the citrate.
  • the citrate resin is then contacted with an acid addition salt prepared as described above and a further anion exchange takesplace converting the acid addition salt to the citrate and leaving the anion of the orginial salt on the resin.
  • the citrate salt can be recovered from the eluate by a number of methods such as evaporation or solvent precipitation. This same procedure can be used to prepare nitrates, sulfates, acetates and other acid addition salts.
  • synergistic benefits of the present invention will be readily obtainable even though either one or the other of the two essential materials may be administered somewhat prior to or subsequent to the administration of the other.
  • each of the two essential materials to be administered will of course also depend upon the variables just mentioned but, in general, the thiazoline or imidazolline will be administered in the range of about 0.1 to milligrams per dose and in the range of about 0.1 to 500 milligrams per day.
  • the synergistic eifect for each part by weight of thiazoline or imidazoline used, there will usually be used from about 0.5 to about 30 parts by weight of anticholinergic agent, and preferably about 0.5 to about 5 parts by weight of the latter.
  • the absolute potency of each of the ingredients will of course be the prime determining factors.
  • the physician or veterinarian will, of course, determine the dosage of each and the total dosage which will be most suitable for a particular application, and as might be expected, it will vary with the age, weight and general health of the patient under treatment and with various other factors which will be determined by the physician or veterinarian in attendance. When they are administered orally a larger quantity will be required to produce the same effect as a smaller quantity given parenterally. Parenteral administration of from 0.1 mg. to 250 mg. of each active agent should be suitable to obtain some effect. Administration can also be by vapor or spray through the mouth or nasal passages.
  • the active pharma ceutical agents may be administered alone but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • they may be administered orally in the form of tablets or capsules containing such excipients as starch, milk sugar, certain types of clay, etc. They may be ad ministered orally in the form of elixirs or oral suspensions which may contain coloring and flavoring agents.
  • They may be injected parenterally and for this use may be prepared in the form of sterile aqueous solutions containing other solutes such as saline or glucose in sufficient quantity to make the solution of isotonic.
  • compositions of the compounds of this invention may be prepared in an oil base such as peanut or sesame oil.
  • compositions useful in the practice of the present invention may take a variety of forms. Various diluents may be employed and the percentage of active ingredients may be varied. It is necessary that the active ingredient or ingredients form a proportion of the com position such that a suitable dosage form will be obtained. Obviously several dosage unit forms can be administered at about the same time. Although compositions with less than 0.005% by weight of either active ingredient are suitable, it is preferred to use compositions containing not less than 0.005% of either active agent because otherwise the amount of carrier becomes excessively large. Activity normally increases with the concentration of the active agent. The percentage by weight of single or combined active agents can be 10, 50, 75, 95 or even higher. Dosage unit forms may be prepared with a minor proportion of a carrier and a major proportion of active materials and vice versa.
  • EXAMPLE 1 A large number of unit capsules are prepared for oral administration by mixing the following ingredients:
  • the mixture is screened through a mesh screen and encapsulated in No. 3 two-piece hard gelatin capsules.
  • EXAMPLE 2 A large number of unit capsules are prepared by oral administration by mixing the following ingredients:
  • Example 3 The active ingredients of Example 1 (20 parts by weight) is dispersed in 100 parts by volume of corn oil and encapsulated in standard soft gelatin capsules.
  • EXAMPLE 4 The active ingredients of Example 2 (20 parts by weight) is dispersed in 100 parts by volume of corn oil and encapsulated in standard soft gelatin capsules.
  • EXAMPLE 5 Tablets for oral administration are prepared by mixing 50 milligrams of the active ingredients of Example 1, 2.5 milligrams of gelatin, 2.5 milligrams of magnesium stearate and 100 milligrams of starch, and forming the mixture into tablets by a conventional tableting machine. Slow release pills and tablets can also be used.
  • EXAMPLE 6 Tablets for oral administration are prepared by mixing 50 milligrams of the active ingredients of Example 2, 2.5 milligrams of gelatin, 2.5 milligrams of magnesium stearate and 100 milligrams of starch, and forming the mixture into tablets by a conventional tableting machine. Slow release pills and tablets can also be used.
  • EXAMPLE 7 A parenteral composition suitable for administration by injection is prepared by dissolving 5% 'by weight of the active ingredients of Example 1 in by volume of physiological saline and sterilizing the resultant solution by filtration. A buffer can be used if desired.
  • EXAMPLE 8 A parenteral composition suitable for administration by injection is prepared by dissolving 5% by weight of the active ingredients of Example 2 in 95% by volume of physiological saline and sterilizing the resultant solution by filtration. A buffer can be used if desired.
  • EXAMPLE 9 2-(5,6,7,8-tetrahydro-l-naphthylamino) 2 thiazoline (0.2 part by weight) is dissolved at a concentration of 2 milligrams per milliliter in a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by weight of physiological saline. The resulting solution is then combined with an equal volume of a solution of 4 milligrams of atropine sulfate dissolved in 1 milliliter of physiological saline.
  • the combined solution is injected into the cephalic vein of a 2 year old beagle dog so that a total of 0.1 milligram of the thiazoline and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog, is administered.
  • a total of 0.1 milligram of the thiazoline and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog is administered.
  • the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-efiects.
  • EXAMPLE 1 O 2 (5,6,7,8 tetrahydro-l-naphthylarnino)-2-imidazoline (0.2 part by weight) is dissolved at a concentration of 2 milligrams per milliliter in a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by Weight of physiological saline. The resulting solution is then combined with an equal volume of a solution of 4 milligrams of atropine sulfate dissolved in 1 milliliter of physiological saline.
  • the combined solution is injected into the cephalic vein of a 2 year old beagle dog so that a total of 0.1 milligram of the imidazo line and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog, is administered.
  • a total of 0.1 milligram of the imidazo line and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog is administered.
  • the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.
  • EXAMPLE 1 l A 1 year old female dog is given an intravenous injection of atropine sulfate dissolved in 0.4% by weight concentration in physiological saline. The injection is sufficient to introduce 0.2 milligram of the atropine sulfate per kilogram of body weight of the dog. The injection of atropine sulfate is followed minutes later by intravenous injection of 2 (5,6,7,8 tetrahydro-l-naphthylamino)-2-thiazoline, dissolved in 0.2% by weight concentration in polyethylene glycol (25 parts) and physiological saline (75 parts), in amount sufiicient to introduce 0.1 milligram of the thiazoline per kilogram of body weight. In about minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-eifects.
  • EXAMPLE 12 A 1 year old female dog is given an intravenous injection of atropine sulfate dissolved in 0.4% by weight concentration in physiological saline. The injection is sufficient to introduce 0.2 milligram of the atropine sulfate per kilogram of body Weight of the dog. The injection of atropine sulfate is followed 10 minutes later by intravenous injection of 2 (5,6,7,8 tetrahydro-l-naphthylamino) 2- imidazoline, dissolved in 0.2% by weight concentration in polyethylene glycol parts) and physiological saline (75 parts), in amount sufficient to introduce 0.1 milligram of the imidazoline per kilogram of body weight. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.
  • 2 5,6,7,8 tetrahydro-l-nap
  • the resulting solution is injected intravenously into a two year-old male dog in an amount to introduce 0.132 miiigram of thiazoline per kilogram of body weight of the dog.
  • This injection is followed in 10 minutes by intravenous administration of a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body weight of the dog.
  • the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state 6 lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.
  • EXAMPLE 14 2 (2,3 dimethylanilino) 2 imidazoline (3 parts by weight) is dissolved in 1000 parts by weight of a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and parts by Weight of physiological saline. The resulting solution is injected intravenously into a 2 yearold male dog in an amount to introduce 0.132 milligram of imidazoline per kilogram of body weight of the dog. This injection is followed in 10 minutes by intravenous administration of a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body Weight of the dog.
  • a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body Weight of the dog.
  • Example 13 is repeated, except that scopolamine hydrobromide is used in place of the atropine sulfate, with similar results.
  • Example 14 is repeated, except that scopolamine hydrobromide is used in place of the atropine sulfate, with similar results.
  • Example 11 is repeated, except that in place of the atropine sulfate there is used an amount of phenyl cyclopentylglycolic acid, N-ethylpiperidinol ester, suflicient to introduce 0.2 milligram of the ester per kilogram of body weight of the dog, with similar results.
  • Example 12 is repeated, except that in place of the atropine sulfate there is used an amount of phenyl cyclopentylglycolic acid, N-ethylpiperidinol ester, sufficient to introduce 0.2 milligram of the ester per kilogram of body weight of the dog, with similar results.
  • Example 9 is repeated, except that in place of the atropine there is used an amount of benzilic acid, betadiethylaminoethyl ester, sufficient to introduce 0.1 milligram of the ester per kilogram of body weight of the dog, with similar results.
  • Example 10 is repeated, except that in place of the atropine there is used an amount of benzilic acid, betadiethylaminoethyl ester, sufiicient to introduce 0.1 milligram of the ester per kilogram of body weight of the dog, with similar results.
  • EXAMPLE 21 Rhesus monkeys are exposed for 5 minutes in a dynamic chamber to an atmosphere containing 400 micrograms per liter of 2-(5,6,7,8tetrahydro-l-naphthylamino)-2- thiazoline and 800 micrograms per liter of scopolarnine aspirated into the chamber in the form of an aerosol. Within 3 to 5 minutes the animals become prostrate, severely depressed and apparently unconscious for a period of about 1 hour.
  • EXAMPLE 22 Rhesus monkeys are exposed for 5 minutes in a dynamic chamber to an atmosphere containing 400 micrograms per liter of 2-(5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline and 800 micrograms per liter of scopolamine aspirated into the chamber in the form of an aerosol. Within 3 to 5 minutes the animals become prostrate, severely depressed and apparently unconscious for a period of about 1 hour.
  • EXAMPLES 2352 The procedures of Examples 9, 10, 11 and 12 are repeated except that the following listed anticholinergic agents and thiazollnes or irnidazolines are substituted in like amounts by Weight for those of Examples 9, 10, ll and 12 respectively. They are administered in like manner and provide like results.
  • Amount Amount Example (mg/kg.) (mg/kg.) Antlchollnergic 0.25 2-(1-naphty1amino)-2 thiazo1ine 0. 500 Atropine sulfate. 0. 25 Z-(I-naphthylamlno)-2-imidazoll 0.500 Do.
  • each of Formulas 1 through 6 X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each separately selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in these four substituents being a maximum of 8; where in each of Formulas 1 through 5, 1 through 3 hydrogen atoms of the moiety selected from the group consisting of naphthyl, partially reduced naphthyl and indanyl can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethly and trifluoromethoxy; and wherein Formula 6 A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and
  • the method comprising administering to a Warmblooded animal Within an hour of each other from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromethoxy.
  • X is selected from the group consisting of sulfur and nitrogen
  • R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8
  • 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.
  • the method comprising administering to a warmblooded animal within an hour of each other, from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromcthoxy.
  • X is selected from the group consisting of sulfur and nitrogen
  • R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4
  • the method comprising administering to a Warmblooded animal within an hour of each other, 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by Weight of a compound of the formula R X*G R 1 NCR L a where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.
  • Method comprising administering to a warm-blooded animal within an hour of each other, 0.5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in eachof these 4 substituents being a maximum 'of 8;.and where 1 through 3 of the hydrogen atoms in the-indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 'mrbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluorornethyl and trifluoromethoxy.
  • X is selected from the group consisting of sulfur and nitrogen
  • R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of
  • I 7' 8 The method comprising administering to a warmblooded animal within an hour of each other 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the
  • anticholinergic agent is selected from the, group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-thiazoline.
  • anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the 17 second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino) -2-imidazoline.
  • anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 thiazoline.
  • said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 irnidazoline.
  • anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro l naphthylamino)-2-thiazoline.
  • anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-imidazoline.
  • anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino)-2-thiazoline.
  • anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 irnidazoline.
  • a composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula
  • X is selected from the group consisting of sulfur and nitrogen
  • R, R R and R are each separately selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in these four substituents being a maximum of 8
  • 1 through 3 hydrogen atoms in the moiety selected from the group consisting of naphthyl, partially reduced naphthyl and indanyl can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy
  • A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and
  • alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifluoromethyl and trifluoromethoxy.
  • composition according to claim 25 where said centrally acting anticholinergic agent is N-ethyl-3-piperidylphenylcyclopentylglycolate.
  • a composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromethoxy.
  • a composition comprising from 0.5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.
  • a composition comprising from .5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula Where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and Where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifiuoromethoxy.
  • a composition comprising from 0.5 to 30 parts by Weight of a centrally acting anticholiner gic agent and l part by Weight of a compound of the formula Where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced consisting of halogen, alkyl f 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromcthoxy.
  • a composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by Weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy.
  • a composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of I through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1
  • composition comprising 1 part by weight of 2- 5,6,7 ,8 tetrahydro l-naphthylamino)-2-thiazoline and 0.5-30 parts by Weight of atropine sulfate.
  • composition comprising 1 part by weight of 2- 5 ,6,7,8-tetrahydrol-naphthylamino -2-imidazoline and 0.530 parts by weight of atropine sulfate.
  • composition comprising 1 part by Weight of 2- (2,3-dimethylanilino)-2-thiazoline and 0.5-3O parts by weight of atropine sulfate.
  • composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-imidazoline and 0.5-30 parts by weight of atropine sulfate.
  • composition comprising 1 part by weight of 2- (5,6,7,8 tetrahydro l-naphthylamino)-2-thiazoline and O.53O parts by weight of scopolamine hydrobromide.
  • composition comprising 1 part by weight of 2- (5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline and 0.5-3O parts by weight of scopolamine hydrobromide.
  • composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-thiazoline and 0.5 to 30 parts by weight of scopolamine hydrobromide.
  • composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-imidazoline and 0.5 to 30 parts by Weight of scopolamine hydrobromide.
  • a composition comprising 1 part by Weight of 2- (5,6,7,8-tetrahydro-l-naphthylamino) 2 thiazoline and 0.530 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N- ethylpiperidinol ester and benzilic acid, beta diethyl aminoethyl ester.
  • a composition comprising 1 part by Weight of 2- (5,6,7,8-tetrahydro-l-naphthylamino) Z-imidazoline and 0.5-30 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N- ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.
  • a composition comprising 1 part by weight of 2- (2,3-dirnethylanilino)-2-thiazoline and 0.5-30 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.
  • a composition comprising 1 part by weight of 2-(2,3-dirnethylanilino)-2-imidazoline and 0.530 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.
  • a composition comprising 1 part by weight of 2-(5,6,7,8,-tetrahydro-l-naphthylamino) 2-thiazoline and 0.5-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
  • a composition comprising 1 part by weight of 2-(5,6,7,8-tetrahydro-l-naphthylamino)-2-imidazo1ine and 05-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
  • a composition comprising 1 part by weight of 2-(2,3-dimethy1anilino)-2-thiazo1ine and 05-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
  • a composition comprising 1 part by weight of 2-(2,3-dimethylani1ino)-2-imidaz01ine and 0.5-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract


5-((-X-C(-R)(-R1)-C(-R2)(-R3)-N=)>C-NH-)TETRALIN (4)

1-((-X-C(-R)(-R1)-C(-R2)(-R3)-N=)>C-NH-)INDAN (3)

1-((-X-C(-R)(-R1)-C(-R2)(-R3)-N=)>C-NH-)TETRALIN (2)

1-((-X-C(-R)(-R1)-C(-R2)(-R3)-N=)>C-NH-)NAPHTHALENE (1)

25. A COMPOSITION COMPRISING FROM 0.5 TO 30 PARTS BY WEIGHT OF A CENTRALLY ACTING ANTICHOLINERGIC AGENT AND 1 PART BY WEIGHT OF A COMPOUND OF THE FORMULA

((-X-C(-R)(-R1)-C(-R2)(-R3)-N=)>C-NH-),A,B,C-BENZENE (6)

4-((-X-C(-R)(-R1)-C(-R2)(-R3)-N=)>C-NH-)INDAN (5) AND
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

Description

United States Patent 3 636 219 ANTICHOLINERGIC C0l\ .[POSlTIONS CONTAIN- ING CERTAIN THIAZOLINES 0R IMIDAZOLINES Rudolf Culik, Kennett Square, Pa., and Jurg A. Schneider,
Wilmington, Del., assignors to E. I. du Pout de Nemours and Company, Wilmington, Del.
No Drawing. Filed Mar. 2, 1964, Ser. No. 348,884
Int. Cl. A61k 27/00 US. Cl. 424-265 48 Claims This invention relates to pharmaceutical compositions useful for both human and veterinary applications. More particularly, this invention relates to synergistic utilization of one or more centrally acting anticholinergic substances and one or more of a class of central nervous sys tern depressants.
The disclosure herein should not be taken as a recommendation to use the disclosed invention in any way without full compliance with US. Food and Drug laws and other laws and governmental regulations which may be applicable.
According to the present invention, an amazing synergism has been noted between a centrally acting anticholi nergic and compounds in a class generically identified as 2-arylamino-Z-thiazolines and 2-arylamino-2-imidazolines. While the thiazolines and imidazolines themselves have activity, some to a remarkable extent, as regulators and in particular depressant of the central nervous system, we have now discovered that, when used with a centrally acting anticholinergic, the synergistic combination according to this invention effects a. profound action, producing a striking depression of central nervous system control of skeletal muscle as well as a striking loss of responses to painful stimuli. This effect resembles a deep surgical anesthesia, producing unconsciousness in the recipient in a very short time.
Centrally acting anticholinergics are a well-recognized class of pharmacologically active substances. As is well known and understood by pharmacologists, these anticholinergics can be naturally occurring or synthetic and are those substances which act to inhibit and have a highly selective blocking action on effector organs innervated by postganglionic cholinergic nerves. As is known to persons skilled in this art, anticholinergic agents containing a quaternary nitrogen moiety are of course not centrally actmg.
Perhaps the best known centrally acting anticholinergics are the natural occurring alkaloids of the belladonna plants. The two most important of these alkaloids are atropine (dl-hyoscyamine) and scopolamine (l-hyoscine) and these two materials are the preferred synergists according to the present invention because of their significantly outstanding synergizing action with the 2-arylamino-Z-thiazolines and the 2-arylamino-2-imidazolines. Also of special importance because of outstanding activity are the centrally acting anticholinergic glycolates.
However, the use of all centrally acting anticholinergic substances is intended to be embraced within the concept of the present invention. Illustrative of such anticholinergics are the following:
Adephenine (registered trademark), also identified as Trasentine (registered trademark) and Z-diethylaminoethyl diphenylacetate ice benactyzine, also identified as beta-diethylaminoethyl benzilate benztropine, also identified as 3-diphenyhnethoxytropane caramiphen, also identified as 1-phenylcyclopentanecarboxylic acid, diethylaminoethyl ester cyclopentolate, also identified as l-hydroxy-alphaphenylcyclopentaneacetic acid, Z-dimethylaminoethyl ester cycrimine, also identified as alpha-cyclopentylalpha-phen yl-l-piperidinepropanol ditran, also identified as N-ethyl-3-piperidyl phenyl cyclopentyl glycolate ethopropazine, also identified as IO-(Z-diethylaminopropyl) phenothiazine oxyphencyclimine, also identified as 1-methyl-1,4,S,6-tetrahydro 2 pyrimidylrnethyl alpha-cyclohexylalphaphenylglycolate piperidolate, also identified as N-ethyl-3-piperidyl diphenylacetate systral, also identified as chlorphenoxamine and beta-dirnethylaminoethyl (p-chloro-alpha-methylbenzhydryl) ether tricyclamol, also identified as procyclidine and alpha-cyclohexyl-alpha-phenyl-l-pyrrolidinepropanol trihexyphenidyl, also identified as alpha-cycloheXyl-alphaphenyl-l-piperidinepropanol In addition to the above-mentioned anticholinergics, other illustrative materials include homatorpine, atroscine, eucatropine, syntropan (amprotropine), pavatrine, bauthine (methantheline), pro-banthine (propantheline), oxypenonium (antrenyl) penthienate (monodral), diphenmethanil (prantal), mepiperphenidol (darstine), dicyclomine (bentyl), aminopentamide (centrine), dibutoline and the like.
As will be readily understood, the centrally acting anticholinergics will most often be used in the form of an acid addition salt with an acid having a pharmaceutically aceptable anion. The term pharmaceutically acceptable anion has a definite meaning to one skilled in the art,
namely, a non-toxic anion of any of the simple acids commercially used to neutralize basic medicinal agents. These acids include, for example, hydrochloric, hydrobromic, hydriodic, sulfuric, succinic, maleic, tartaric, citric, glyco'lic, and others. The pharmaceutical activity of the molecule is primarily but not necessarily exclusively a function of the cation.
By way of further illustration of the salts of anticholinergic agents, it can be mentioned that atropine is preferably used as the hydrobromide, hydrochloride, methylbrornide, methylnitrate, salicylate, sulfate, atropinesulfuric acid, valerate, aurichloride, platinichloride, oxalate or picrate; scopolamine as the hydrobromide, hydrochloride, aurichloride, auribromide, picrate, methylbromide, methylnitrate or aminoxide; Adephenine (registered trademark) as the hydrochloride; 'benactyzine as the hydrochloride; benztropine as the methanesulfonate; caramiphen as the hydrochloride or ethanedisulfonate; cycrimine as the hydrochloride; oxyphencyclimine as the hydrochloride; systral as the hydrochloride; and trihexyphenidyl as the hydrochloride.
The second essential ingredient of the synergistic compositions of the present invention is a 2-arylamino-2- thiazoline or a 2-arylamino-2-imidazoline having central nervous system depressant activity. Suitable Z-arylaminothiazolines or 2-arylamino-2-imidazolines include those of the following formulas:
NH-C
R xix-n X-(L-R In each of the above formulas, X is S or N; R, R R and R are the same or different and can each be hydrogen or an alkyl group of 1 through 4 carbons with the total number of carbons in these 4 substituents being a maximum of 8. In the compounds of Formulas 1 through 5, the hydrogen atoms in the naphthyl, the partially reduced naphthyl or the indanyl groups may be replaced with substituents such as halogen, e.g., chlorine, bromine, fluorine and iodine, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy. Up through three such substituents can be present.
In Formula 6, A can be hydrogen, alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons, and preferably 1 or 2 carbons, or halogen including chlorine, bromine and fluorine; B can be alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons and preferably 1 or 2 carbons, or halogen including chlorine, bromine and fluorine; and C can be hydrogen, alkyl of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxy of 1 through 4 carbons and preferably 1 or 2 carbons, halogen including chlorine, bromine and fluorine, alkylthio of 1 through 4 carbons and preferably 1 or 2 carbons, alkoxyalkyl wherein the alkoxy portion has 1 or 2 carbons and the alkyl portion has 1 or 2 4 carbons, alkylamino of 1 or 2 carbons, dialkylamino where the alkyl group can be the same or dilferent and each has 1 or 2 carbons, trifiuoromethyl or trifluoromethoxy.
PREPARATION The thiazoline compounds used in this invention are made in the manner described for the thiazoline compounds of U5. Pat. 2,027,030. Appropriate substitution of starting materials such as naphthyl-isothio-cyanates and indanyl-isothio-cyanates for the phenyl-isothiocyanates will produce the desired compounds.
The imidazoline compounds used in this invention are made in the manner described for the imidazolines of US. Pat. 2,899,426. Appropriate substitution of starting materials as will be known to an expert in the art produces the desired compounds.
Generally, the compounds used in this invention are crystalline solids. They can be readily prepared by reaction of the appropriately selected arylamine and an appropriate alkyl thiocyanate to form the corresponding N-aryl-N'-(beta-substituted ethyl)thiourea, followed by heating in a suitable solvent to close the thioazoline ring. Alternatively, the thiourea can be prepared by reaction between an appropriate aryl thiocyanate and an appropriate alkylamine followed by the ring closure.
In the foregoing procedures, the reaction between the amine and thiocyanate can conveniently be carried out in a suitable inert organic solvent including both aromatic and aliphatic hydrocarbon solvents. Halogenated, oxygenated or nitrated hydrocarbon solvents are useful. Representative solvents are benzene, chloroform, carbon tetrachloride, ethylene dichloride, chlorobenzene, toluene, xylene, nitrobenzene, and nitrotoluene. Temperatures in the range from 0 to C. are suitable.
By reference to the reaction described above, it can be seen that in the ordinary practice of the process of the invention, the thiazolines, and the irnidazolines produced will be hydrobromides, hydrochlorides, hydriodides, methanesulfonic acids or p-toluenesulfonic acids. These acids can be converted to other pharmaceutically acceptable acids by procedures well known to those skilled in the art. One highly useful method comprises contacting the acid addition salt with a basic anion exchange resin, for example, a highly basic compound such as the one available from Rohm & Haas Company under the name Amberlite IRA-400. This resin is a polyquaternary ammonium compound which is prepared by chloromethylatiug a highly cross-linked copolymer of styrene and divinylbenzene followed by treatment of the chloromethylated material with a tertiary amine such as trimethylamine. To prepare an acid addition salt of this invention, for example, the citrate, the resin is first contacted with an aqueous solution of citric acid whereupon an anion exchange takes place converting the quaternary halide to the citrate. The citrate resin is then contacted with an acid addition salt prepared as described above and a further anion exchange takesplace converting the acid addition salt to the citrate and leaving the anion of the orginial salt on the resin. The citrate salt can be recovered from the eluate by a number of methods such as evaporation or solvent precipitation. This same procedure can be used to prepare nitrates, sulfates, acetates and other acid addition salts.
Illustrative of the compounds within the scope of Formula 1 above are the following:
2- 3 ,4-dichlorol-naphthyl am ino -2-thi azol ine 2- 3,4-dichloro-l-naphthyl amino -2-imidazoline 2- 3-bromol -naphthylamino) -4-metthyl-2-thiazoline 2- (3-bromo-l-naphthylarnino) -4-rnethyl-2-imidazoline.
2- (4-ethyll-naphthylamino -4,S-dimethyl-Z-thiazoliue 2- (4-ethyl-1-naphthylamino -4,S-dimethyl-Z-imidazoline 2-(3 ,4,5-triiodo- 1 -naphtl1ylamino -2-thiazoline 2- 3,4,5 -triiodo-1-naphthylamino -2-imidazo1ine 2- 3,4-bismethylthiol-naphthylamino -4-butyl-2- thiazoline 2- 5,6,7 ,8-tetrahydro-3,4,5-triiodo-1 -naphthylamino) -4,5-
dimethyl-Z-imidazoline 2- ,6,7,8-tetrahydro-4-isopropyll-naphthylamino) -2- thiazoline 2- 5,6,7,8-tetrahydro-4-isopropy1- l-naphthylamino -2 imidazoline 2- (5,6,7,8-tetrahydro-4-trifiuor0methyl-l-naphthylamino Z-thiazolines 2- 5,6,7,8-tetrahydro-4-trifluor0methyll-naphthylamino Z-imidazoline 2- (5,6,7,8-tetrahydro-4-trifluoromethoxyl-n aphthylamino) -2-thiazolines 2- 5 6,7,8-tetr ahydro-4-trifluoromethoxyl-naphthylamino) -2-imidazoline Illustrative of the compounds within the scope of Formula 5 above are the following:
2- (4-iudanylamino) -2-thiazoline 2- 4-indanylamino) -2-irnidazoline 2-(2-chloro-4-indanylan1ino) -2-thiazoline 2-(2-chloro-4-indanylamino)-2-imidazoline 2- 2,5 -diiodo-4-indanylamino -2-thiazoline 2- 2,5 -diiodo4-indanylamino -2-imidazoline 2-(3,5-bispropylthio-4-indanylamino)-2-thiazoline 2- 3 ,5 -bispropylthio-4-indanylamino -2-imidazoline 2-(2-methyl-4-indany1amino)-2-thiazoline 2-(2-methyl-4-indanylamino)-2-imidazoline Illustrative of the compounds within the scope of Formula 6 are the following:
2- 2-toluidino -2thiazoline 2- Z-toluidino -2-imidazoline 2- 2,3-dimethylanilino )-2-thiazoline 2- (2,3 -dimethylanilino) -2-imidazoline 2-( 3-chloro-2-methylanilino -2-thiazoline 2- 3 -chloro-2-methylanilino -2-imidazoline 2- (Z-ethylanilino -2-thiazoline 2- 2-ethylanilino -2-imidazo1ine 2-( 3,4-dimethylanilino) -2-thiazoline 2- 3 ,4-dimethylanilino -2irnidazoline 2-( 3-isopropylaniliuo -2-thiazoline 2- 3-isopropylanilino -2-imidazoline 2- (2,3 ,4-trichloroanilino -2thiazoline 2- (2,3 ,4-trichloroanilino) -2-imid azoline 2- (4-methoxy-2-methylanilino -2-thiaz0line 2- (4-methoXy-2-methylanilino -2-imidazoline 5-methyl-2- 2,3-dimethylanilino -2-thiazo1ine S-methyl-Z- 2,3-dimethylanilino -2-imidazoline 4-ethyl-2- (2, 3 -dimethylanilino -2-thiazoline 4-ethy1-2- (2,3-dimethylanilino -2-imid azoline 4,4-dimethyl-2- 2-methyl-3-chloroanilin0 -2-thiazoline 4,4-dimethyl2- (Z-methyl-B-chloroanilino -2-imidazoline 5 -butyl-2- (Z-methylanilino -2-thiazoline 5-butyl-2- Z-methylanilino -2-imidazoline 2- Z-dimethylaminoanilino) -2-thiazoline 2- (Z-dimethylaminoanilino -2-imidazoline 2- (3 -methylthioanilino -2-thiazoline 2- (3-methylthio anilino -2-imidazolinne 2- (Z-trifiuoromethylanilino) -2-thiaz0line 2- (Z-trifiuoromethylanilino -2-imidazoline 2- (2-trifluoromethoxy-3-methylanilino -2-thiazoline 2- 2-trizfluoromethoXy-3 -methylanilino -2-imidazoline 2- 2,4,5 -trimethylanilino) -2-thiazoline 2-(2,4,5-trimethylanilino -2-imidazoline 4-methyl-2- 2-methyl-5-isopropylanilino -2-thiazoline 4methyl-2- 2-methyl-5 -isopropylanilino 2-imidazoline 2- 2,5 -dimethoxyanilino -2-thiazoline 2-(2,5-dimetboxyani1ino)-2-imidazoline S-methyl-Z- 2,4-dimethoxy-5-chloroanilino -2- thiazoline S-methyl-Z- (2,4-dimethoxy-S-chloroanilino -2- imidazoline 2-( Z-fluoroanilino) -2-thiazoline 2- 2- fluoroanilino -2-imidazoline 2- (2-bromo-4-methylanilino -2-thiazoline 2- 2-bromo-4-methy1anilino) -2-imidazoline 8 2-( 2,5 -diethoxyanilino) -2-thiazoline 2- 2,5 -diethoxyanilino) -2-imidazoline 2- 3-chloro-4-methylanilino) -2.-thiazoline 2- 3-chloro-4-methylanilino -2-imidazoline 2- 2,6-diethylanilino) -2-thiazoline 2- 2,6-diethylanilino -2-imidazoline 2- 4-chloro-Z-trifiuoromethylanilino) -2-thiazoline 2- (4-chloro-2-tritluoromethylanilino -2-imidazoline 2- 3-chloro-4-fluoroaniliuo )-2-thiazoline 2- 3-chloro-4-fiuoroanilino -2-imidazoline 2- (4 fluoro-2-methylauilino -2-thiazoline 2-(41fluoro-2-methylani1in0)-2-imidazoline In the practice of the present invention it should be fully appreciated that administration of the anticholinergic and the thiazolines and the imidazolines for the intended profound depressant effect will be more or less concurrent, i.e., united in action, and not necessarily simultaneously, i.e., in the same pharmaceutical formulation or dosage unit. Thus, it will be understood that the synergistic benefits of the present invention will be readily obtainable even though either one or the other of the two essential materials may be administered somewhat prior to or subsequent to the administration of the other. For example, for gradual inducement of profound central nervous system depression with apparent unconsciousness in a patient, it may under some circumstances be desirable to administer first the thiazoline or the imidazoline, perhaps orally, followed by within say 30 minutes or an hour by administration, perhaps by injection, of the synergistic amount of the anticholinergic agent.
Of course, the precise length of time which can elapse between administration of the anticholinergic and the thiazoline or the imidazoline, or vice versa, to still obtain the synergistic co-action of the compounds has not been determined for each combination of the two different materials possible according to this invention. This precise time lag will depend on the amount of each administered, the condition of the recipient, the absorption characteristics of each material, the dosage form or method, the nature of the effect desired, etc., as will be determined by the attendant physician or veterinarian. Generally speaking, it is believed that provided the dosage of each are sufficient, the synergistic action isobtainable if the two components are administered within, say, 2 or 3 hours of each other.
The amount of each of the two essential materials to be administered will of course also depend upon the variables just mentioned but, in general, the thiazoline or imidazolline will be administered in the range of about 0.1 to milligrams per dose and in the range of about 0.1 to 500 milligrams per day. For the synergistic eifect, for each part by weight of thiazoline or imidazoline used, there will usually be used from about 0.5 to about 30 parts by weight of anticholinergic agent, and preferably about 0.5 to about 5 parts by weight of the latter. The absolute potency of each of the ingredients will of course be the prime determining factors.
As mentioned above, in general, the physician or veterinarian will, of course, determine the dosage of each and the total dosage which will be most suitable for a particular application, and as might be expected, it will vary with the age, weight and general health of the patient under treatment and with various other factors which will be determined by the physician or veterinarian in attendance. When they are administered orally a larger quantity will be required to produce the same effect as a smaller quantity given parenterally. Parenteral administration of from 0.1 mg. to 250 mg. of each active agent should be suitable to obtain some effect. Administration can also be by vapor or spray through the mouth or nasal passages.
In animal tests to date no synergism of cardiovascular actions has thus far been noted. Furthermore, based on tests to date, it is believed that the surprising synergism in inducement of profound central nervous system depression obtained according to the present invention is achieved without at the same time substantially altering the normally expected effect of centrally acting anticholinergic agents on the heart rate.
In the practice of this invention, the active pharma ceutical agents may be administered alone but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets or capsules containing such excipients as starch, milk sugar, certain types of clay, etc. They may be ad ministered orally in the form of elixirs or oral suspensions which may contain coloring and flavoring agents. They may be injected parenterally and for this use may be prepared in the form of sterile aqueous solutions containing other solutes such as saline or glucose in sufficient quantity to make the solution of isotonic. For intramuscular administration compositions of the compounds of this invention may be prepared in an oil base such as peanut or sesame oil.
Compositions useful in the practice of the present invention may take a variety of forms. Various diluents may be employed and the percentage of active ingredients may be varied. It is necessary that the active ingredient or ingredients form a proportion of the com position such that a suitable dosage form will be obtained. Obviously several dosage unit forms can be administered at about the same time. Although compositions with less than 0.005% by weight of either active ingredient are suitable, it is preferred to use compositions containing not less than 0.005% of either active agent because otherwise the amount of carrier becomes excessively large. Activity normally increases with the concentration of the active agent. The percentage by weight of single or combined active agents can be 10, 50, 75, 95 or even higher. Dosage unit forms may be prepared with a minor proportion of a carrier and a major proportion of active materials and vice versa.
The following examples are given solely for the purpose of illustration and are not to be construed as limitations of this invention, many variations of which are possible without departing from the spirit or scope thereof.
EXAMPLE 1 A large number of unit capsules are prepared for oral administration by mixing the following ingredients:
Parts by weight 2-(5,6,7,8 tetrahydro 1 naphthylamino) 2- thiazoline 650 Scopolamine hydrobromide 1,300 Lactose U.S.P. 8,000 Dry pyrogenic silica Si with particle size of 0.015 micron, surface area of 200 m. /gm., and
bulk density of 2.2 lbs/cu. ft. (Cabosil,
Cabot Corp.) 50
After mixing, the mixture is screened through a mesh screen and encapsulated in No. 3 two-piece hard gelatin capsules.
EXAMPLE 2 A large number of unit capsules are prepared by oral administration by mixing the following ingredients:
Parts by weight 2-(5,6,7,8 tetrahydro 1 naphthylamino) 2- imidazoline 650 Scopolamine hydrobromide 1,300 Lactose U.S.P. 8,000 Dry pyrogenic silica SiO with particle size of 0.015 micron, surface area of 200 m. /gm., and
bulk density of 2.2 lb./cu. ft. (Cabosil,
Cabot Corp.)
10 After mixing, the mixture is screened through a 40 mesh screen and encapsulated in No. 3 two-piece hard gelatin capsules.
EXAMPLE 3 The active ingredients of Example 1 (20 parts by weight) is dispersed in 100 parts by volume of corn oil and encapsulated in standard soft gelatin capsules.
EXAMPLE 4 The active ingredients of Example 2 (20 parts by weight) is dispersed in 100 parts by volume of corn oil and encapsulated in standard soft gelatin capsules.
EXAMPLE 5 Tablets for oral administration are prepared by mixing 50 milligrams of the active ingredients of Example 1, 2.5 milligrams of gelatin, 2.5 milligrams of magnesium stearate and 100 milligrams of starch, and forming the mixture into tablets by a conventional tableting machine. Slow release pills and tablets can also be used.
EXAMPLE 6 Tablets for oral administration are prepared by mixing 50 milligrams of the active ingredients of Example 2, 2.5 milligrams of gelatin, 2.5 milligrams of magnesium stearate and 100 milligrams of starch, and forming the mixture into tablets by a conventional tableting machine. Slow release pills and tablets can also be used.
EXAMPLE 7 A parenteral composition suitable for administration by injection is prepared by dissolving 5% 'by weight of the active ingredients of Example 1 in by volume of physiological saline and sterilizing the resultant solution by filtration. A buffer can be used if desired.
EXAMPLE 8 A parenteral composition suitable for administration by injection is prepared by dissolving 5% by weight of the active ingredients of Example 2 in 95% by volume of physiological saline and sterilizing the resultant solution by filtration. A buffer can be used if desired.
EXAMPLE 9 2-(5,6,7,8-tetrahydro-l-naphthylamino) 2 thiazoline (0.2 part by weight) is dissolved at a concentration of 2 milligrams per milliliter in a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by weight of physiological saline. The resulting solution is then combined with an equal volume of a solution of 4 milligrams of atropine sulfate dissolved in 1 milliliter of physiological saline. The combined solution is injected into the cephalic vein of a 2 year old beagle dog so that a total of 0.1 milligram of the thiazoline and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog, is administered. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-efiects.
EXAMPLE 1 O 2 (5,6,7,8 tetrahydro-l-naphthylarnino)-2-imidazoline (0.2 part by weight) is dissolved at a concentration of 2 milligrams per milliliter in a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by Weight of physiological saline. The resulting solution is then combined with an equal volume of a solution of 4 milligrams of atropine sulfate dissolved in 1 milliliter of physiological saline. The combined solution is injected into the cephalic vein of a 2 year old beagle dog so that a total of 0.1 milligram of the imidazo line and 0.2 milligram of the atropine sulfate, per kilogram of body weight of the dog, is administered. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.
EXAMPLE 1 l A 1 year old female dog is given an intravenous injection of atropine sulfate dissolved in 0.4% by weight concentration in physiological saline. The injection is sufficient to introduce 0.2 milligram of the atropine sulfate per kilogram of body weight of the dog. The injection of atropine sulfate is followed minutes later by intravenous injection of 2 (5,6,7,8 tetrahydro-l-naphthylamino)-2-thiazoline, dissolved in 0.2% by weight concentration in polyethylene glycol (25 parts) and physiological saline (75 parts), in amount sufiicient to introduce 0.1 milligram of the thiazoline per kilogram of body weight. In about minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-eifects.
EXAMPLE 12 A 1 year old female dog is given an intravenous injection of atropine sulfate dissolved in 0.4% by weight concentration in physiological saline. The injection is sufficient to introduce 0.2 milligram of the atropine sulfate per kilogram of body Weight of the dog. The injection of atropine sulfate is followed 10 minutes later by intravenous injection of 2 (5,6,7,8 tetrahydro-l-naphthylamino) 2- imidazoline, dissolved in 0.2% by weight concentration in polyethylene glycol parts) and physiological saline (75 parts), in amount sufficient to introduce 0.1 milligram of the imidazoline per kilogram of body weight. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.
EXAMPLE l3 2-(2,3-dimethylanilino)-2-thiazoline (3 parts by weight) is dissolved in 1000 parts by Weight of a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and 75 parts by weight of physiological saline. The resulting solution is injected intravenously into a two year-old male dog in an amount to introduce 0.132 miiigram of thiazoline per kilogram of body weight of the dog. This injection is followed in 10 minutes by intravenous administration of a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body weight of the dog. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state 6 lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-effects.
EXAMPLE 14 2 (2,3 dimethylanilino) 2 imidazoline (3 parts by weight) is dissolved in 1000 parts by weight of a mixture of 25 parts by weight of polyethylene glycol (Carbowax 400) and parts by Weight of physiological saline. The resulting solution is injected intravenously into a 2 yearold male dog in an amount to introduce 0.132 milligram of imidazoline per kilogram of body weight of the dog. This injection is followed in 10 minutes by intravenous administration of a normal saline solution of atropine sulfate, sufiicient to introduce 0.5 milligram of atropine sulfate per kilogram of body Weight of the dog. In about 15 minutes the animal becomes depressed and passes into a state of deep central nervous system depression in which the animal does not respond to painful stimuli. This state lasts for about 1 to 2 hours following which the animal recovers normal functions with no deleterious after-efiects.
EXAMPLE 15 Example 13 is repeated, except that scopolamine hydrobromide is used in place of the atropine sulfate, with similar results.
EXAMPLE 16 Example 14 is repeated, except that scopolamine hydrobromide is used in place of the atropine sulfate, with similar results.
EXAMPLE 17 Example 11 is repeated, except that in place of the atropine sulfate there is used an amount of phenyl cyclopentylglycolic acid, N-ethylpiperidinol ester, suflicient to introduce 0.2 milligram of the ester per kilogram of body weight of the dog, with similar results.
EXAMPLE 18 Example 12 is repeated, except that in place of the atropine sulfate there is used an amount of phenyl cyclopentylglycolic acid, N-ethylpiperidinol ester, sufficient to introduce 0.2 milligram of the ester per kilogram of body weight of the dog, with similar results.
EXAMPLE 19 Example 9 is repeated, except that in place of the atropine there is used an amount of benzilic acid, betadiethylaminoethyl ester, sufficient to introduce 0.1 milligram of the ester per kilogram of body weight of the dog, with similar results.
EXAMPLE 20 Example 10 is repeated, except that in place of the atropine there is used an amount of benzilic acid, betadiethylaminoethyl ester, sufiicient to introduce 0.1 milligram of the ester per kilogram of body weight of the dog, with similar results.
EXAMPLE 21 Rhesus monkeys are exposed for 5 minutes in a dynamic chamber to an atmosphere containing 400 micrograms per liter of 2-(5,6,7,8tetrahydro-l-naphthylamino)-2- thiazoline and 800 micrograms per liter of scopolarnine aspirated into the chamber in the form of an aerosol. Within 3 to 5 minutes the animals become prostrate, severely depressed and apparently unconscious for a period of about 1 hour.
EXAMPLE 22 Rhesus monkeys are exposed for 5 minutes in a dynamic chamber to an atmosphere containing 400 micrograms per liter of 2-(5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline and 800 micrograms per liter of scopolamine aspirated into the chamber in the form of an aerosol. Within 3 to 5 minutes the animals become prostrate, severely depressed and apparently unconscious for a period of about 1 hour.
EXAMPLES 2352 The procedures of Examples 9, 10, 11 and 12 are repeated except that the following listed anticholinergic agents and thiazollnes or irnidazolines are substituted in like amounts by Weight for those of Examples 9, 10, ll and 12 respectively. They are administered in like manner and provide like results.
Amount Amount Example (mg/kg.) (mg/kg.) Antlchollnergic 0.25 2-(1-naphty1amino)-2 thiazo1ine 0. 500 Atropine sulfate. 0. 25 Z-(I-naphthylamlno)-2-imidazoll 0.500 Do.
0.2 2-(4-methoxy-l-naphthylamino)-2-thlazoline. 0. 400 Scopolamine hydrobromlde. 0. 2 2-(4-methoxy-l-naphthylamlno)-2-lmldazoline 0. 400 Do. 0.2 2-(4-methoxy-1-naphthylamlno)-2-thlaz0llne 5. Benzotyzine. 0. 2 2-(i-mathoxy-l-naphthylamino)-2-lmldazollne.. 5.00 Do. 0. 2 2-(2-methyl-l-naphthylamlno)-2-thlazoline 0. 400 Scopolarnlne hydrobromlde. 0. 2 2-(2-methyl-l-naphthylamlno)-2-imldazollne 0. 400 Do. 1.0 2-(4-methyl-1-naphthylamino)-2-thlazollne 1.00 Atropine sulfate. 1. 0 2-(4-methyl-l-naphthylamlno)-2imldazollne 1.00 D 0. 0.1 2-(5,6,7,B-tetrahydro-l-naphthylamino) -2-thlazollne 10.00 Trasentino. 0. 1 2-(5,6,7,S-tetrahydro-l-naphthylarnino)-2-lmldaz0llne 10. 00 Do. 0. 1 2-(4-metliyl-5,6,7,s-tetrahydro-l-naphthylamlno)-2-tl11azoline 0. 50 Benztropine. 0.1 2-(4-methyl-5,6,7,8-tetrahydro-1naphthylamlno)-2-lmidazollne 0.50 Do. 0.5 2-(4-methoxy-5,6,7,8-tetrahydro-l-naphthylamlno)-2-thlazollne 1. 00 Dltran 0. 5 2-(4-methoxy-5,6,7,8-tetrahydro-1-naphthylamluo)-2-imldazollne 1. 00 D0. 0. 1 2-(1,2,3,4-tetrahydro-l-naphthylamlno)-2-thlaz0llne. 25. 00 Caramiphen. 0. 1 2-(1,2,3,4-tetrahydro-l-naphthylamino)-2-imldazollne 25.00 0. 0.25 2-(2-methylanilino)-2-thiazoline 0.50 Oyclopentolate. 0.25 2-(2-methylanilino) -2-imldazoline 0.50 o.
0. 5 2-(2-ethylanlliuo)-2-thlazoline 5.00 Cycrimine hydrochloride. 0.5 2-(2-ethylanilion)-2-i.midazollne 5. 00 Do. 0. 1 2(2,3-dimethylanilino)-2-thlazoline. 50. 00 Ethopropazine. 0. 1 2-(2,3-dimethylanillno)2-lm1dazollno 50.00 Do. 0. 2-(2-chloro-2-methylanillno) -2-thlaz0line 50. 00 Plparldolate. 0.25 2-(2-chloro-2-methylanillno)-2-imidazoline 50. 00 Do.
0. 1 2-(2,6-dlmethylanlliuo)-2-thiazoline 20.00 Oxyphencyclimine. 0. 1 2-(2,6-dlmethylanilino)2lrnidazoline 20. 00 Do. 0. 75 244-111ethoxy-Zqnethylanillno) -2-thiazoline 5.00 Trlcyclamol. 0.75 2-(4 methoxy-2-methylan1lino) -2-lmidazoline 5. 00 Do.
where in each of Formulas 1 through 6 X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each separately selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in these four substituents being a maximum of 8; where in each of Formulas 1 through 5, 1 through 3 hydrogen atoms of the moiety selected from the group consisting of naphthyl, partially reduced naphthyl and indanyl can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethly and trifluoromethoxy; and wherein Formula 6 A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifiuoromethyl and tritluoromethoxy.
2. The method according to claim 1 wherein said centrally acting anticholinergic is N-ethyl-3-piperidylphenylcyclopentyl glycolate.
3. The method comprising administering to a Warmblooded animal Within an hour of each other from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromethoxy.
4. The method comprising administering to a warmblooded animal Within an hour of each other from 0.5
to parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and Where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.
5. The method comprising administering to a warmblooded animal within an hour of each other, from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromcthoxy.
6. The method comprising administering to a Warmblooded animal within an hour of each other, 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by Weight of a compound of the formula R X*G R 1 NCR L a where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.
7. Method comprising administering to a warm-blooded animal within an hour of each other, 0.5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in eachof these 4 substituents being a maximum 'of 8;.and where 1 through 3 of the hydrogen atoms in the-indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 'mrbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluorornethyl and trifluoromethoxy. I 7' 8. The method comprising administering to a warmblooded animal within an hour of each other 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifluoromethyl and trifluoromethoxy.
9. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-(5,6,7,8-tetrahydro-l-naphthylamino)-2-thiazoline.
10. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-(5,6,7,S-tctrahydro-l-naphthylamino)-2irnidazoline.
11. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-( 2,3-dimethylanilino -2-thiazoline.
12. The method according to claim 1 where said anticholinergic agent is atropine sulfate and the second ingredient is 2-(2,3-dimethylanilino) -Z-imidazoline.
'13. The method according to claim 1 where said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-thiazoline.
14. The method according to claim lwhere said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-imidazo1ine.
15. The method according to claim 1 where said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(2,3-dimethylanilino)-2-thiazoline.
16. The method according to claim 1 where said anticholinergic agent is scopolamine hydrobromide and the second ingredient is 2-(2,3-dimetliylanilino)2-imidazoline.
17. The method according to claim 1 where said anticholinergic agent is selected from the, group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-thiazoline.
18. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the 17 second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino) -2-imidazoline.
19. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 thiazoline.
20. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 irnidazoline.
21. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro l naphthylamino)-2-thiazoline.
22. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(5,6,7,8-tetrahydro 1 naphthylamino)-2-imidazoline.
23. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino)-2-thiazoline.
24. The method according to claim 1 where said anticholinergic agent is selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester and the second ingredient is 2-(2,3-dimethylanilino) 2 irnidazoline.
25. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula Where in each of the Formulas 1 through 6 X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each separately selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in these four substituents being a maximum of 8; where in each of Formulas 1 through 5, 1 through 3 hydrogen atoms in the moiety selected from the group consisting of naphthyl, partially reduced naphthyl and indanyl can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy; and Where in Formula (6) A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoXy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, al-
koxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino where each alkyl group has 1 through 2 carbons, trifluoromethyl and trifluoromethoxy.
26. A composition according to claim 25 Where said centrally acting anticholinergic agent is N-ethyl-3-piperidylphenylcyclopentylglycolate.
27. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromethoxy.
28. A composition comprising from 0.5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifiuoromethoxy.
29. A composition comprising from .5 to 30 parts by Weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula Where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and Where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifiuoromethoxy.
30. A composition comprising from 0.5 to 30 parts by Weight of a centrally acting anticholiner gic agent and l part by Weight of a compound of the formula Where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the partially reduced naphthyl group can be replaced consisting of halogen, alkyl f 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifluoromethyl and trifluoromcthoxy.
31. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by Weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; and where 1 through 3 of the hydrogen atoms in the indanyl group can be replaced with a member selected from the group consisting of halogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, alkylthio of 1 through 4 carbons, trifiuoromethyl and trifluoromethoxy.
32. A composition comprising from 0.5 to 30 parts by weight of a centrally acting anticholinergic agent and 1 part by weight of a compound of the formula where X is selected from the group consisting of sulfur and nitrogen; R, R R and R are each selected from the group consisting of hydrogen and alkyl of 1 through 4 carbons with the total number of carbons in each of these 4 substituents being a maximum of 8; A is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons and halogen; B is selected from the group consisting of alkyl of I through 4 carbons, alkoxy of 1 through 4 carbons and halogen; and C is selected from the group consisting of hydrogen, alkyl of 1 through 4 carbons, alkoxy of 1 through 4 carbons, halogen, alkylthio of 1 through 4 carbons, alkoxyalkyl wherein the alkoxy portion has 1 through 2 carbons and the alkyl portion has 1 through 2 carbons, alkylamino of 1 through 2 carbons, dialkylamino Where each alkyl group has 1 through 2 carbons, trifiuoromethyl and trifi uoromethoxy.
33. A composition comprising 1 part by weight of 2- 5,6,7 ,8 tetrahydro l-naphthylamino)-2-thiazoline and 0.5-30 parts by Weight of atropine sulfate.
34. A composition comprising 1 part by weight of 2- 5 ,6,7,8-tetrahydrol-naphthylamino -2-imidazoline and 0.530 parts by weight of atropine sulfate.
35. A composition comprising 1 part by Weight of 2- (2,3-dimethylanilino)-2-thiazoline and 0.5-3O parts by weight of atropine sulfate.
36. A composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-imidazoline and 0.5-30 parts by weight of atropine sulfate.
37. A composition comprising 1 part by weight of 2- (5,6,7,8 tetrahydro l-naphthylamino)-2-thiazoline and O.53O parts by weight of scopolamine hydrobromide.
38. A composition comprising 1 part by weight of 2- (5,6,7,8-tetrahydro-1-naphthylamino)-2-imidazoline and 0.5-3O parts by weight of scopolamine hydrobromide.
39. A composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-thiazoline and 0.5 to 30 parts by weight of scopolamine hydrobromide.
40. A composition comprising 1 part by weight of 2- (2,3-dimethylanilino)-2-imidazoline and 0.5 to 30 parts by Weight of scopolamine hydrobromide.
41. A composition comprising 1 part by Weight of 2- (5,6,7,8-tetrahydro-l-naphthylamino) 2 thiazoline and 0.530 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N- ethylpiperidinol ester and benzilic acid, beta diethyl aminoethyl ester.
42. A composition comprising 1 part by Weight of 2- (5,6,7,8-tetrahydro-l-naphthylamino) Z-imidazoline and 0.5-30 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N- ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.
43. A composition comprising 1 part by weight of 2- (2,3-dirnethylanilino)-2-thiazoline and 0.5-30 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.
44. A composition comprising 1 part by weight of 2-(2,3-dirnethylanilino)-2-imidazoline and 0.530 parts by weight of a compound selected from the group consisting of phenylcyclopentylglycolic acid, N-ethylpiperidinol ester and benzilic acid, beta diethylaminoethyl ester.
45. A composition comprising 1 part by weight of 2-(5,6,7,8,-tetrahydro-l-naphthylamino) 2-thiazoline and 0.5-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
46. A composition comprising 1 part by weight of 2-(5,6,7,8-tetrahydro-l-naphthylamino)-2-imidazo1ine and 05-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
47. A composition comprising 1 part by weight of 2-(2,3-dimethy1anilino)-2-thiazo1ine and 05-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
48. A composition comprising 1 part by weight of 2-(2,3-dimethylani1ino)-2-imidaz01ine and 0.5-30 parts by weight of benzilic acid, beta-diethylaminoethyl ester.
22 References Cited UNITED STATES PATENTS 3,287,469 11/1966 Harvey 2603 09.6 2,027,031 1/ 193 6 Engelmann 26044 2,870,160 1/1959 Bloom 260307 3,287,469 11/1966 Harvy 260309.6
LELAND A. SEBASTIAN, Primary Examiner US. Cl. X.R
260306.8 R, 309.6; 424247, 251, 267, 268, 269, 270, 273 and 274

Claims (1)

  1. 25. A COMPOSITION COMPRISING FROM 0.5 TO 30 PARTS BY WEIGHT OF A CENTRALLY ACTING ANTICHOLINERGIC AGENT AND 1 PART BY WEIGHT OF A COMPOUND OF THE FORMULA
US348884A 1964-03-02 1964-03-02 Anticholinergic compositions containing certain thiazolines or imidazolines Expired - Lifetime US3636219A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34888464A 1964-03-02 1964-03-02

Publications (1)

Publication Number Publication Date
US3636219A true US3636219A (en) 1972-01-18

Family

ID=23369982

Family Applications (1)

Application Number Title Priority Date Filing Date
US348884A Expired - Lifetime US3636219A (en) 1964-03-02 1964-03-02 Anticholinergic compositions containing certain thiazolines or imidazolines

Country Status (1)

Country Link
US (1) US3636219A (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882229A (en) * 1972-07-21 1975-05-06 Nordmark Werke Gmbh Composition and method for shrinking mucous membranes
US3978221A (en) * 1975-03-04 1976-08-31 Smithkline Corporation Methods for improving the feed intake of meat producing animals
FR2370736A1 (en) * 1976-11-15 1978-06-09 Basf Ag NEWS 1-ACYL 2-IMIDAZOLINES AND METHOD FOR THEIR PREPARATION
US4287201A (en) * 1980-03-03 1981-09-01 Merck & Co., Inc. Anovulatory method and chicken feed compositions
US4363751A (en) * 1980-08-04 1982-12-14 Merck & Co., Inc. Catalyst for the preparation of 4-cyanothiazole and process for preparing the catalyst
EP0081924A1 (en) * 1981-11-20 1983-06-22 Alcon Laboratories, Inc. Topical compostions for lowering intraocular pressure
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
US4476135A (en) * 1981-02-19 1984-10-09 Sandoz Ltd. Amino-2,1,3-benzothiadiazole and -benzoxadiazole derivatives, their preparation and pharmaceutical compositions containing them
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4517199A (en) * 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4644007A (en) * 1981-11-20 1987-02-17 Alcon Laboratories, Inc. 3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
US4788209A (en) * 1987-02-17 1988-11-29 Merrell Dow Pharmaceuticals Inc. Antifungal 2-anilinothiazolines
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5151440A (en) * 1990-02-28 1992-09-29 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5223498A (en) * 1989-02-16 1993-06-29 The Boots Company Plc Phenylamidine and phenylguanidine derivatives and their use as antidiabetic agents
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
WO1995011021A1 (en) * 1993-10-22 1995-04-27 Allergan Use of 2-(2-alkylphenylamino)-oxazolines, -thiazolines and -imidazolines as alpha 2 adrenergic agents
US5731337A (en) * 1994-07-11 1998-03-24 Allergan Conformationally rigid bicycle and adamantane derivatives useful as α2
WO1998046572A1 (en) * 1997-04-11 1998-10-22 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US20030187045A1 (en) * 2001-12-21 2003-10-02 Uwe Heinelt Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
US20080293569A1 (en) * 2005-11-25 2008-11-27 Basf Se Indanyl- and Tetrahydronaphthyl-Amino-Azoline Compounds for Combating Animal Pests
US20080300285A1 (en) * 2005-08-15 2008-12-04 Syngenta Crop Protection, Inc. Chemical Compounds
WO2009023758A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Heterocyclyl substituted fused carbocyles useful in the treatment of conditions such as glaucoma and pain
WO2009023757A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Therapeutic compounds
US20100137385A1 (en) * 2006-02-15 2010-06-03 Bayer Cropscience Ag Insecticidal Substituted Amino Heterocyclic and Heteroaryl Derivatives
US20100167925A1 (en) * 2006-08-07 2010-07-01 Basf Se Substituted Azolin-2-yl-Amino Compounds
WO2011044229A1 (en) 2009-10-06 2011-04-14 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882229A (en) * 1972-07-21 1975-05-06 Nordmark Werke Gmbh Composition and method for shrinking mucous membranes
US3978221A (en) * 1975-03-04 1976-08-31 Smithkline Corporation Methods for improving the feed intake of meat producing animals
FR2370736A1 (en) * 1976-11-15 1978-06-09 Basf Ag NEWS 1-ACYL 2-IMIDAZOLINES AND METHOD FOR THEIR PREPARATION
US4269990A (en) * 1976-11-15 1981-05-26 Basf Aktiengesellschaft 1-Acyl-2-imidazolines and their manufacture
US4287201A (en) * 1980-03-03 1981-09-01 Merck & Co., Inc. Anovulatory method and chicken feed compositions
US4363751A (en) * 1980-08-04 1982-12-14 Merck & Co., Inc. Catalyst for the preparation of 4-cyanothiazole and process for preparing the catalyst
US4476135A (en) * 1981-02-19 1984-10-09 Sandoz Ltd. Amino-2,1,3-benzothiadiazole and -benzoxadiazole derivatives, their preparation and pharmaceutical compositions containing them
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
US4515800A (en) * 1981-11-20 1985-05-07 Icilio Cavero Method of lowering intraocular pressure using phenylimino-imidazoles
US4517199A (en) * 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4644007A (en) * 1981-11-20 1987-02-17 Alcon Laboratories, Inc. 3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
EP0081924A1 (en) * 1981-11-20 1983-06-22 Alcon Laboratories, Inc. Topical compostions for lowering intraocular pressure
US4788209A (en) * 1987-02-17 1988-11-29 Merrell Dow Pharmaceuticals Inc. Antifungal 2-anilinothiazolines
US5223498A (en) * 1989-02-16 1993-06-29 The Boots Company Plc Phenylamidine and phenylguanidine derivatives and their use as antidiabetic agents
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
US5151440A (en) * 1990-02-28 1992-09-29 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
WO1995011021A1 (en) * 1993-10-22 1995-04-27 Allergan Use of 2-(2-alkylphenylamino)-oxazolines, -thiazolines and -imidazolines as alpha 2 adrenergic agents
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US5708015A (en) * 1993-10-22 1998-01-13 Allergan Method for using pharmaceutical compositions containing 2-(2-alkyphenyl-amino)-thiazolines as adrenergic agents
US5731337A (en) * 1994-07-11 1998-03-24 Allergan Conformationally rigid bicycle and adamantane derivatives useful as α2
US6706747B2 (en) 1994-07-11 2004-03-16 Allergan, Inc. Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
US6569884B2 (en) 1994-07-11 2003-05-27 Allergan Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
US6319935B1 (en) 1994-07-11 2001-11-20 Allergan Sales, Inc. Conformationally rigid bicyclic and adamantane derivatives useful as α2-adrenergic blocking agents
US6294566B1 (en) 1997-04-11 2001-09-25 Synaptic Pharmaceutical Corporation Imidazoline derivatives and uses thereof
US6777426B2 (en) 1997-04-11 2004-08-17 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6093727A (en) * 1997-04-11 2000-07-25 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
WO1998046572A1 (en) * 1997-04-11 1998-10-22 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
US6353006B1 (en) 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
US7179829B2 (en) * 2001-12-21 2007-02-20 Sanofi-Aventis Deutschland Gmbh Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them
US20050004198A1 (en) * 2001-12-21 2005-01-06 Aventis Pharma Deutschland Gmbh Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic, and medicament comprising them
US20030187045A1 (en) * 2001-12-21 2003-10-02 Uwe Heinelt Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
US7960310B2 (en) 2005-08-15 2011-06-14 Syngenta Participations Ag Method of combating and controlling insects
US20080300285A1 (en) * 2005-08-15 2008-12-04 Syngenta Crop Protection, Inc. Chemical Compounds
US8309739B2 (en) 2005-08-15 2012-11-13 Syngenta Limited Chemical compounds
US20110218341A1 (en) * 2005-08-15 2011-09-08 Syngenta Crop Protection, Inc. Chemical compounds
US20080293569A1 (en) * 2005-11-25 2008-11-27 Basf Se Indanyl- and Tetrahydronaphthyl-Amino-Azoline Compounds for Combating Animal Pests
US7981437B2 (en) * 2005-11-25 2011-07-19 Basf Se Indanyl- and tetrahydronaphthyl-amino-azoline compounds for combating animal pests
US8178567B2 (en) 2006-02-15 2012-05-15 Fmc Corporation Insecticidal substituted amino heterocyclic and heteroaryl derivatives
US20100137385A1 (en) * 2006-02-15 2010-06-03 Bayer Cropscience Ag Insecticidal Substituted Amino Heterocyclic and Heteroaryl Derivatives
US20100167925A1 (en) * 2006-08-07 2010-07-01 Basf Se Substituted Azolin-2-yl-Amino Compounds
CN101855213A (en) * 2007-08-15 2010-10-06 阿勒根公司 therapeutic compound
JP2010536780A (en) * 2007-08-15 2010-12-02 アラーガン インコーポレイテッド Therapeutic compound
US20110178143A1 (en) * 2007-08-15 2011-07-21 Allergan, Inc. Therapeutic compounds
JP2010536781A (en) * 2007-08-15 2010-12-02 アラーガン インコーポレイテッド Heterocyclic substituted fused carbocycles useful in the treatment of conditions such as glaucoma and pain
WO2009023757A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Therapeutic compounds
WO2009023758A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Heterocyclyl substituted fused carbocyles useful in the treatment of conditions such as glaucoma and pain
JP2014139175A (en) * 2007-08-15 2014-07-31 Allergan Inc Therapeutic compounds
US8815923B2 (en) 2007-08-15 2014-08-26 Allergan, Inc. Therapeutic compounds
WO2011044229A1 (en) 2009-10-06 2011-04-14 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
US9040532B2 (en) 2009-10-06 2015-05-26 Allergan, Inc. Alpha adrenergic receptor modulators
US9522150B2 (en) 2009-10-06 2016-12-20 Allergan, Inc. Alpha adrenergic receptor modulators
EP3584237A1 (en) 2009-10-06 2019-12-25 Allergan, Inc. Alpha adrenergic receptor modulators

Similar Documents

Publication Publication Date Title
US3636219A (en) Anticholinergic compositions containing certain thiazolines or imidazolines
DE3688296T2 (en) MEDICINES FOR TREATING EMERGENCY.
DE69725345T2 (en) USE OF 5-HT4 ANTAGONISTS TO OVERCOME THE GASTROINTESTINAL DAMAGE CAUSED BY SEROTONIN REINVISION INHIBITORS
US3679798A (en) Composition comprising arylaminooxazoline and antichloligeneric agent
DE69412662T2 (en) Angiotensin II antagonists for the treatment of viral diseases
CA2036375A1 (en) Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
JPS62424A (en) Medicinal composition
US4312879A (en) Clonidine and lofexidine as antidiarrheal agents
DE3031703C2 (en)
WO1994013284A1 (en) New use of 5-ht3 receptor antagonists
US4259346A (en) Bradycardiac pharmaceutical compositions and method of use
DE68912740T2 (en) Acyclic derivatives with diuretic properties.
US3733423A (en) Hydrogenated ergot alkaloid compositions and methods of using same
US3360434A (en) Method for reducing blood pressure with phenylalanine derivatives
SK11695A3 (en) Use of 3-benzoyl-3,7-diazobicyclo£3,3,1| nonane compounds as antiarhytmic effective medicament and method of its production
DE68915595T2 (en) Use of isoxazolinones as cerebroactive drugs.
DE69122480T2 (en) Use of phenylethanol aminotetralins to produce an anti-depressant and anti-stress drug
US4363809A (en) Organic compounds
US3354036A (en) Method of producing depression
US3879535A (en) Anesthetic compositions and methods of use
JPH03502802A (en) Antiemetic ergoline derivative
US3366542A (en) Pharmaceutical preparations containing gamma-amino-beta-(3:4-chlorophenyl)-butyric acd
DE2351609A1 (en) Parkinsonism treatment compsn - containing ergocornine or 2-bromo-alpha ergocryptine
US3371013A (en) Methods of effecting antidepressant therapy
DE2340632C2 (en) Use of 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole or its salts in the supportive treatment for the regression and alleviation of neoplasms